High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Parkinson Disease
In brief
Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.
Key facts
- Study ID
- NCT05268887
- Run by
- Massachusetts Institute of Technology
- People needed
- 40
- Starts
- 2022-02-09
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-03-31
Who can join
Age: 45 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist
- Subject is Hoehn \& Yahr stage 2 to 3
- Subject has a Montreal Cognitive Assessment (MOCA) score ≥26.
- Subject is > 45 and <90 years of age.
- proficient in speaking, reading, and understanding English
- capable of providing informed written consent
- Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required.
- Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions
You may not qualify if…
- Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia)
- history of any psychiatric illness that would pose a safety risk
- diagnosis of dementia or other neurological conditions
- currently taking sedative medications that are clinically contraindicated
- has undergone recent change (<1 month) in medication
- recent drug or alcohol abuse or dependence
- laboratory results the would pose safety risk
- concurrently or has participated in other clinical trial investigation within 3 months
- pregnant
- no healthcare
- history of epilepsy, stroke, or seizure in past 24 months
- diagnosis of migraines
- have certain implantable medical devices
- contraindications for MRI
- life expectancy of less than 2 years
Where it is running
- Massachusetts Institute of Technology — Cambridge, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.